Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6966437 | 1.00 | HDAC1 (0.58) | HDAC1HDAC7TDP1L3MBTL1HDAC8 | |
| SCHEMBL10667117 | 0.98 | HDAC1 (0.56) | HDAC1HDAC7TDP1L3MBTL1HDAC8 | |
| SCHEMBL10666776 | 0.98 | HDAC1 (0.56) | HDAC1HDAC7TDP1L3MBTL1HDAC8 | |
| SCHEMBL6954199 | 0.95 | HDAC7 (0.52) | HDAC1HDAC7TDP1L3MBTL1HDAC8 | |
| SCHEMBL3359985 | 0.95 | HDAC7 (0.52) | HDAC1HDAC7TDP1L3MBTL1HDAC8 | |
| SCHEMBL7898753 | 0.95 | HDAC7 (0.52) | HDAC1HDAC7TDP1L3MBTL1HDAC8 | |
| SCHEMBL876560 | 0.89 | SMN1; SMN2 (0.53) | HDAC1HDAC7SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL13686537 | 0.87 | HDAC1 (0.53) | HDAC1HDAC7TDP1L3MBTL1HDAC8 | |
| SCHEMBL11686163 | 0.83 | HDAC1 (0.59) | HDAC1HDAC7TDP1L3MBTL1HDAC8 | |
| SCHEMBL8527564 | 0.82 | HDAC1 (0.49) | HDAC1HDAC7TDP1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980242-B2 | Aliphatic prodrug linker | ASCENDIS PHARMA GMBH (DK) | 2015-03-17 | — | — | US | disclosed |
| US-8980242-B2 | Aliphatic prodrug linker | ASCENDIS PHARMA GMBH (DK) | 2015-03-17 | — | — | US | disclosed |
| EP-1909845-B1 | N,N-BIS-(2-HYDROXYETHYL) GLYCINE AMIDE AS LINKER IN POLYMER CONJUGATED PRODRUGS | ASCENDIS PHARMA AS (DK) | 2012-08-15 | — | — | EP | disclosed |
| US-20100291021-A1 | ALIPHATIC PRODRUG LINKER | ASCENDIS PHARMA GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100291021-A1 | ALIPHATIC PRODRUG LINKER | ASCENDIS PHARMA GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-6953788-B1 | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6953788-B1 | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6953788-B1 | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6770640-B1 | EMPHYSEMA | AVENTIS PHARMACEUTICALS INC. | 2004-08-03 | — | — | US | disclosed |
| CN-1150205-C | 3-mercaptoacetylamino-1,5-subsd. 2-oxo-azepon derivatives useful as inhibitor of metrix metalloproteinase | ���µ�˹ҩ�﹫˾ | 2004-05-19 | — | — | CN | disclosed |
| EP-1140818-A1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | Aventis Pharmaceuticals Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6262080-B1 | 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase | AVANTIS PHARMACEUTICALS INC. | 2001-07-17 | — | — | US | disclosed |
| WO-2000040564-A1 | N-CARBOXYMETHYL SUBSTITUTED BENZOLACTAMS AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040552-A1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040578-A1 | 3-(THIO-SUBSTITUTED AMIDO)-LACTAMS USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040577-A1 | 1-CARBOXYMETHYL-2-OXO-AZEPAN DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF MMP-12 | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040553-A1 | 3-SUBSTITUTED PYRROLIDINES USEFUL AS INHIBITORS OF MATRIX METALLO-PROTEINASES | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| CN-1234039-A | 3-mercaptoacetylamino-1, 5-disubstituted-2-oxo-azepane derivatives as matrix metalloproteinase inhibitors | HOECHST MARION ROUSSEL INC (US) | 1999-11-03 | — | — | CN | disclosed |
| EP-0928291-A1 | 3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-14 | — | — | EP | disclosed |
| WO-1998012211-A1 | 3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | HOECHST MARION ROUSSEL, INC. (US) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291021-A1 | ALIPHATIC PRODRUG LINKER | PAICS, AADAC, TK1 | HDAC1 47/4885HDAC7 46/4885TDP1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.